Amonafide in Combination With Cytarabine in Secondary AML

ClinicalTrials.gov ID: NCT00273884

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00273884. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 2 Open-Label Study of Amonafide L-Malate in Combination With Cytarabine in Subjects With Secondary Acute Myeloid Leukemia (AML)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This protocol is designed to assess the safety and efficacy of amonafide in combination with cytarabine in subjects with previously untreated secondary AML.

Study identification

NCT ID: NCT00273884
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Xanthus Pharmaceuticals, Inc.; Industry
Enrollment: 80 participants

Conditions and interventions

Conditions

Acute Myeloid Leukemia

Interventions

Amonafide L-Malate Drug
Cytarabine Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 2005 (Type not available)
Primary completion: Not listed
Completion: Apr 2009 (Type not available)
Last update posted: Feb 19, 2007

2005 – 2009

United States locations

U.S. sites: 19
U.S. states: 15
U.S. cities: 19

Facility	City	State	ZIP	Site status
University of Alabama at Birmingham Comprehensive Cancer Center	Birmingham	Alabama	35294-3300	—
City of Hope National Medical Center	Duarte	California	91010	—
UCLA Medical Center	Los Angeles	California	90024	—
Scripps Cancer Center	San Diego	California	92121	—
University of Colorado Health Sciences Center, Anschutz Cancer Center	Aurora	Colorado	80010	—
University of Florida Health Science Center	Gainesville	Florida	32610-0277	—
Northwestern University, Robert H. Lurie Comprehensive Cancer Center	Chicago	Illinois	60611	—
St. Francis Cancer Research Foundation (formerly Indiana Oncology Hematology Consultants and American Health Network of Indiana LLC, Oncology Division)	Indianapolis	Indiana	46202	—
Dana Farber Cancer Institute	Boston	Massachusetts	02115	—
University of Massachusetts Memorial Medical Center	Worcester	Massachusetts	01655	—
University of Michigan	Ann Arbor	Michigan	48109-0848	—
University of Nebraska Medical Center	Omaha	Nebraska	98198 7835	—
Roswell Park Cancer Institute	Buffalo	New York	75246	—
Duke University Medical Center	Durham	North Carolina	27710	—
Wake Forest University Health Sciences	Winston-Salem	North Carolina	27157	—
MUSC - Hollings Cancer Center	Charleston	South Carolina	29425	—
Baylor University Medical Center	Dallas	Texas	75246	—
West Virginia University Medical Center	Morgantown	West Virginia	26506-9162	—
Medical College of Wisconsin	Milwaukee	Wisconsin	53226	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00273884, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 19, 2007 · Synced Nov 14, 2026